Physician
Kings Daughters Medical Specialties INC
Kings Daughters Medical Specialties INC was paid $3.25M by Medicaid between Jan 2018 and Dec 2024, across 22 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 45% of everything it billed.
33Billing provider infoKINGS DAUGHTERS MEDICAL SPECIALTIES INC
PORTSMOUTH, OH 45662
PORTSMOUTH, OH 45662
33aNPI1275871907assigned 01/31/2013
33bProvider typeFamily Medicine Physician
28Total paid$3.25M
24GClaims113,544
24DCodes billed22
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Ohio
Rank by total paid#32 of 739
Median peer was paid$30K
This provider vs. median110×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WHITLATCH, KRISTIE controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,602 | $622K | |
| 2019 | 17,051 | $513K | |
| 2020 | 11,166 | $360K | |
| 2021 | 14,894 | $466K | |
| 2022 | 19,159 | $453K | |
| 2023 | 17,934 | $401K | |
| 2024incomplete | 15,738 | $432K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 45% | 32,879 | 30,877 | $1.45M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 38% | 43,593 | 40,994 | $1.25M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 8.4% | 7,349 | 6,950 | $273K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.1% | 15,023 | 13,750 | $102K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.0% | 1,163 | 1,034 | $66K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.6% | 1,006 | 935 | $53K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 996 | 915 | $29K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,507 | 2,279 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,343 | 6,704 | $10K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 148 | 143 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 270 | 262 | $2K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 215 | 199 | $1K |
10 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 34 | $1K |
| 99283 | Emergency room visit (moderate) | <1% | 20 | $751.33 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 175 | $699.19 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 61 | $323.52 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 94 | $305.42 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 373 | $235.95 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 13 | $40.00 |
| 36415 | Collection of venous blood by venipuncture | <1% | 12 | $29.69 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 224 | $27.13 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 46 | $11.35 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWHITLATCH, KRISTIE (CEO/PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.